Highlights the importance of recognizing the heterogeneity of hypertrophic cardiomyopathy to direct individualized therapy.
Answers are grounded in this paper and cite their sources.
May support individualized HCM therapy; leaves open prospective validation of heterogeneity-guided strategies.
HCM is a heterogeneous disease genotypically, phenotypically, pathophysiologically, clinically, and therapeutically. In decisions on the management of these patients, it is important to recognize this heterogeneity and to direct therapy at the predominant abnormalities.
No takes yet. Share an insight, caveat, or question.
Wigle et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: